Enanta Not To Exercise Co-development Option For ABT-493

(RTTNews) - Enanta Pharmaceuticals, Inc., (ENTA) said Monday that it has decided not to exercise its co-development option for ABT-493, Enanta's next-generation protease inhibitor for hepatitis C virus being developed in Enanta's collaboration with AbbVie Inc. (ABBV).

As per the original collaboration agreement signed in December 2006, Enanta will be eligible for certain regulatory approval milestones as well as royalties on net sales allocable to ABT-493 from worldwide sales of any ABT-493-containing regimens.

Enanta also said that it has reached agreement with AbbVie regarding the net sales allocations for royalty calculations for ABT-450-containing regimens, as well as any regimens containing ABT-493. ABT-450 is the first clinical-stage protease inhibitor candidate developed within the Enanta-AbbVie collaboration, and ABT-493 is the second.